Rep.angola 48a Regulatory News (42RV)

Name: THE REPUBLIC OF ANGOLA

Date: 22 May 2026

Re: Publication of Final Terms

The pricing supplement in relation to the issue of U.S.$600,000,000 9.244 per cent. Notes due 2031 by the Republic of Angola (the "Issuer") (to be consolidated and form a single series with the U.S.$1,000,000,000 9.244 per cent. Notes due 2031 issued by the Issuer on 15 October 2025) under the Issuer's Global Medium Term Note Programme (the "Series 5 Pricing Supplement") is available for viewing. To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/5101F_1-2026-5-22.pdf

The pricing supplement in relation to the issue of U.S.$900,000,000 9.875 per cent. Notes due 2037 by the Issuer (to be consolidated and form a single series with the U.S.$1,000,000,000 9.875 per cent. Notes due 2037 issued by the Issuer on 31 March 2026) under the Issuer's Global Medium Term Note Programme (the "Series 8 Pricing Supplement") is available for viewing. To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/5101F_2-2026-5-22.pdf

For further information, please contact: 

Dorivaldo F. S. Teixeira

Director - Public Debt Management Unit, Republic of Angola

Ministry of Finance Building

Largo da Matumba

Luanda

Republic of Angola

+244 222 706 077

E-Mail: dorivaldo.teixeira@minfin.gov.ao

Please read the disclaimer below "Disclaimer - Intended Addressees" before attempting to access this service, as your right to do so is conditional upon complying with the requirements set out below.

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in this announcement, the Series 5 Pricing Supplement and the Series 8 Pricing Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Series 5 Pricing Supplement and the Series 8 Pricing Supplement) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Series 5 Pricing Supplement and the Series 8 Pricing Supplement is not addressed. Prior to relying on the information contained in the Series 5 Pricing Supplement and the Series 8 Pricing Supplement, you must ascertain from the Series 5 Pricing Supplement and the Series 8 Pricing Supplement whether or not you are part of the intended addressees of the information contained therein.

In particular, this announcement, the Series 5 Pricing Supplement and the Series 8 Pricing Supplement do not constitute an offer or invitation to subscribe for, or purchase, securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction. The securities referred to in the announcement, the Series 5 Pricing Supplement and the Series 8 Pricing Supplement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act, and the rules and regulations thereunder. The Issuer does not intend to register any of the securities referred to in the announcement, the Series 5 Pricing Supplement and the Series 8 Pricing Supplement in the United States or to conduct a public offering of the securities referred to in the announcement, the Series 5 Pricing Supplement and the Series 8 Pricing Supplement in the United States or elsewhere.

The Series 5 Pricing Supplement and the Series 8 Pricing Supplement have been made available to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission and consequently none of the Issuer or its advisers accepts any liability or responsibility whatsoever in respect of any difference between the Series 5 Pricing Supplement and the Series 8 Pricing Supplement made available to you in electronic format and the hard copy version available to you on request from the Issuer.

Your right to access this service is conditional upon complying with the above requirement.